Palvella Therapeutics, Inc. Common Stock PVLA
i
Market datapartial · fetched 2026-11-13T01:27:46.867Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T21:14:07.926516684Z
FundamentalsAlpha Vantage · unavailable
Palvella Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 178.04 | 104.5% | 16.8% | |||
| 25Δ | 168.75 | 78.7% | 10.8% | 145.94 | 61.8% | 6.9% |
| 30Δ | 163.12 | 62.1% | 7.2% | 148.23 | 57.8% | 5.8% |
| 35Δ | 159.82 | 52.3% | 5.2% | 150.37 | 55.3% | 4.7% |
| 40Δ | 158.22 | 50.7% | 4.5% | 152.00 | 57.7% | 4.3% |
| 45Δ | 156.62 | 49.0% | 3.7% | 153.63 | 60.0% | 3.8% |
| 50Δ | 155.02 | 47.4% | 3.0% | 155.35 | 62.7% | 3.4% |
| 55Δ | 153.48 | 49.4% | 2.7% | 157.56 | 67.1% | 3.1% |
| 60Δ | 151.95 | 51.3% | 2.4% | 159.77 | 71.5% | 2.8% |
| 65Δ | 150.41 | 53.3% | 2.0% | 161.91 | 70.6% | 2.3% |
| 70Δ | 148.79 | 53.1% | 1.7% | 164.03 | 69.0% | 1.8% |
| 75Δ | 147.13 | 52.1% | 1.3% | 166.92 | 70.2% | 1.4% |
| 80Δ | 145.47 | 51.1% | 1.0% | 170.58 | 73.7% | 1.1% |
20Δ
- Pseudo strike
- 178.04
- IV
- 104.5%
- B/E move
- 16.8%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 168.75
- IV
- 78.7%
- B/E move
- 10.8%
- Pseudo strike
- 145.94
- IV
- 61.8%
- B/E move
- 6.9%
30Δ
- Pseudo strike
- 163.12
- IV
- 62.1%
- B/E move
- 7.2%
- Pseudo strike
- 148.23
- IV
- 57.8%
- B/E move
- 5.8%
35Δ
- Pseudo strike
- 159.82
- IV
- 52.3%
- B/E move
- 5.2%
- Pseudo strike
- 150.37
- IV
- 55.3%
- B/E move
- 4.7%
40Δ
- Pseudo strike
- 158.22
- IV
- 50.7%
- B/E move
- 4.5%
- Pseudo strike
- 152.00
- IV
- 57.7%
- B/E move
- 4.3%
45Δ
- Pseudo strike
- 156.62
- IV
- 49.0%
- B/E move
- 3.7%
- Pseudo strike
- 153.63
- IV
- 60.0%
- B/E move
- 3.8%
50Δ
- Pseudo strike
- 155.02
- IV
- 47.4%
- B/E move
- 3.0%
- Pseudo strike
- 155.35
- IV
- 62.7%
- B/E move
- 3.4%
55Δ
- Pseudo strike
- 153.48
- IV
- 49.4%
- B/E move
- 2.7%
- Pseudo strike
- 157.56
- IV
- 67.1%
- B/E move
- 3.1%
60Δ
- Pseudo strike
- 151.95
- IV
- 51.3%
- B/E move
- 2.4%
- Pseudo strike
- 159.77
- IV
- 71.5%
- B/E move
- 2.8%
65Δ
- Pseudo strike
- 150.41
- IV
- 53.3%
- B/E move
- 2.0%
- Pseudo strike
- 161.91
- IV
- 70.6%
- B/E move
- 2.3%
70Δ
- Pseudo strike
- 148.79
- IV
- 53.1%
- B/E move
- 1.7%
- Pseudo strike
- 164.03
- IV
- 69.0%
- B/E move
- 1.8%
75Δ
- Pseudo strike
- 147.13
- IV
- 52.1%
- B/E move
- 1.3%
- Pseudo strike
- 166.92
- IV
- 70.2%
- B/E move
- 1.4%
80Δ
- Pseudo strike
- 145.47
- IV
- 51.1%
- B/E move
- 1.0%
- Pseudo strike
- 170.58
- IV
- 73.7%
- B/E move
- 1.1%
Options history
Table
| Date | IV (%) |
|---|---|
| 52.39% | |
| 52.77% | |
| 52.00% | |
| 52.99% | |
| 53.72% | |
| 54.13% | |
| 53.03% | |
| 52.12% | |
| 50.59% | |
| 52.97% |
Biotechnology
PYPD
PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX) platform to address…
More →PYXS
Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immunotherapies for treating…
More →QTTB
Q32 Bio Inc. (QTTB) is a pioneering biotechnology firm focused on the development of advanced antibody-based therapies for autoimmune diseases and immune response optimization.…
More →QURE
uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in…
More →RANI
Rani Therapeutics Holdings Inc. is an innovative biotechnology company transforming the landscape of drug delivery with its proprietary RaniPill™ technology, which enables the…
More →RAPP
Description unavailable
More →